Most of this will play out in the New Year, but I thought the readership might like to see "what's next" -- besides an appeal obviously -- in the Merck/Idenix $2.54 billion nominal patent award. In sum, there is quite a long road yet ahead -- no matter which side ultimately prevails.
Here is that four page status report (a PDF file) -- on post trial motions, and scheduling.
Now you know. Falling now, as silent as the snows, then. . . . smile.